Sort   by:  
 Page size 
ProteomicsCrenigacestat inhibits osteogenic differentiation of human valve interstitial cells and seems promising for treatment of cardiovascular calcification
Vascular calcification is common pathology various forms of which presented in the half of humans. Calcific aortic valve disease (CAVD) is one of the most dangerous forms of vascular calcification. Despite high mortality there is no target therapy against CAVD. Thus, we tested crenigacestat (LY30394...
ORGANISM(S): Homo sapiens (Human) 
2022-10-04 | PXD029632 | Pride
Valve intersticial cells Timstof pro Vascular calcification Ly3039478 Notch inhibitors Crenigacestat Calcific aortic valve disease Shotgun proteomics 
GenomicsEffect of Crenigacestat treatment in xenograft model of HUCCT1 intrahepatic cholangiocarcinoma
Effect of Crenigacestat treatment in xenograft model of HUCCT1 intrahepatic cholangiocarcinoma
PRJNA630916 | ENA
UnknownA phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors.
Not available
S-EPMC7960611 | biostudies-literature
UnknownCrenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition.
Not available
S-EPMC9703776 | biostudies-literature
TranscriptomicsEffect of Crenigacestat treatment in xenograft model of HUCCT1 intrahepatic cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (iCCA) is a difficult type of cancer to diagnose, extremely aggressive and resistant to therapeutic options with an increased incidence and mortality over time. The overexpression of Notch pathway is implicated in iCCA to create an ecosystem that drives the tumor aggr...
ORGANISM(S): Homo sapiens 
2022-04-27 | GSE150024 | GEO
UnknownCrenigacestat (LY3039478) inhibits osteogenic differentiation of human valve interstitial cells from patients with aortic valve calcification in vitro.
Not available
S-EPMC9556293 | biostudies-literature
UnknownNotch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia.
Not available
S-EPMC12317248 | biostudies-literature
UnknownCrenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
Not available
S-EPMC7370218 | biostudies-literature
TranscriptomicsTargeting Cancer Associated Fibroblasts/Tumor Cells Cross-Talk Inhibits Intrahepatic Cholangiocarcinoma Progression
Cancer associated fibroblasts (CAFs), mainly responsible for the desmoplastic reaction hallmark of intrahepatic Cholangiocarcinoma (iCCA), likely take a role in tumour aggressiveness and resistance to therapy, although the molecular mechanisms involved are unknown. Aim of the study is to investigate...
ORGANISM(S): Homo sapiens 
2024-11-22 | GSE273905 | GEO
UnknownTargeting cancer-associated fibroblasts/tumor cells cross-talk inhibits intrahepatic cholangiocarcinoma progression via cell-cycle arrest.
Not available
S-EPMC11484308 | biostudies-literature
Sort   by:  
 Page size